March 2025's ASX Penny Stocks To Watch
As Australian shares are poised for a slight decline, with the ASX 200 expected to drop by 0.3% at the start of Week 13, investors are closely monitoring market movements amid ongoing economic uncertainty. Despite their vintage name, penny stocks remain a relevant investment area, often representing smaller or newer companies that offer potential growth opportunities at lower price points. With strong balance sheets and solid fundamentals, these stocks can provide upside potential while mitigating some risks typically associated with this segment of the market.
Name
Share Price
Market Cap
Financial Health Rating
CTI Logistics (ASX:CLX)
A$1.61
A$125.6M
★★★★☆☆
MotorCycle Holdings (ASX:MTO)
A$2.06
A$152.04M
★★★★★★
Accent Group (ASX:AX1)
A$1.795
A$1.02B
★★★★☆☆
EZZ Life Science Holdings (ASX:EZZ)
A$1.585
A$74.77M
★★★★★★
IVE Group (ASX:IGL)
A$2.39
A$370.18M
★★★★★☆
GTN (ASX:GTN)
A$0.62
A$121.75M
★★★★★★
Bisalloy Steel Group (ASX:BIS)
A$3.19
A$151.37M
★★★★★★
Regal Partners (ASX:RPL)
A$2.83
A$949.17M
★★★★★★
NRW Holdings (ASX:NWH)
A$2.88
A$1.32B
★★★★★☆
LaserBond (ASX:LBL)
A$0.37
A$43.41M
★★★★★★
Click here to see the full list of 978 stocks from our ASX Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand with a market cap of A$1.02 billion.
Operations: Accent Group generates revenue from two primary segments: Retail, contributing A$1.30 billion, and Wholesale, adding A$475.92 million.
Market Cap: A$1.02B
Accent Group Limited, with a market cap of A$1.02 billion, trades at 56.3% below its estimated fair value and is considered a good relative value compared to peers. The company has experienced management but an inexperienced board, which recently saw new appointments to strengthen governance. Despite unstable dividends and negative earnings growth over the past year, Accent Group maintains high-quality earnings and covers debt well with operating cash flow. Recent results show sales growth from A$742.16 million to A$775.96 million in the last half-year, indicating resilience in challenging market conditions despite lower net profit margins than last year.
Take a closer look at Accent Group's potential here in our financial health report.
Review our growth performance report to gain insights into Accent Group's future.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Fenix Resources Limited is involved in the exploration, development, and mining of mineral tenements in Western Australia, with a market cap of A$218.64 million.
Operations: The company generates revenue from three main segments: Mining (A$244.98 million), Logistics (A$84.02 million), and Port Services (A$40.44 million).
Market Cap: A$218.64M
Fenix Resources, with a market cap of A$218.64 million, has shown stable weekly volatility over the past year. The company is financially sound with short-term assets exceeding liabilities and more cash than total debt. Recent earnings reported sales of A$130.97 million for the half-year ended December 2024, but net income decreased significantly from A$22.05 million to A$1.87 million compared to the previous year, reflecting lower profit margins at 5.1%. Despite negative earnings growth last year and an inexperienced management team, Fenix's debt is well covered by operating cash flow and interest payments are manageable through EBIT coverage.
Click to explore a detailed breakdown of our findings in Fenix Resources' financial health report.
Explore Fenix Resources' analyst forecasts in our growth report.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Horizon Oil Limited, along with its subsidiaries, focuses on the exploration, development, and production of oil and gas properties in China, New Zealand, and Australia with a market cap of A$349.44 million.
Operations: The company generates revenue primarily from its exploration and development activities in China, contributing $60.53 million, and New Zealand, contributing $34.26 million.
Market Cap: A$349.44M
Horizon Oil, with a market cap of A$349.44 million, has seen its earnings decline significantly over the past year, with net income dropping from US$18.26 million to US$6.58 million for the half-year ended December 2024. Despite trading at a significant discount to estimated fair value and having an experienced board, the company faces challenges such as lower profit margins and unsustainable dividends not covered by earnings or cash flow. However, Horizon's debt is well managed with strong interest coverage by EBIT and operating cash flow exceeding total debt levels. Short-term assets exceed liabilities but don't cover long-term obligations fully.
Unlock comprehensive insights into our analysis of Horizon Oil stock in this financial health report.
Assess Horizon Oil's future earnings estimates with our detailed growth reports.
Jump into our full catalog of 978 ASX Penny Stocks here.
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:AX1 ASX:FEX and ASX:HZN.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
39 minutes ago
- Yahoo
Australia's Monash IVF reports second embryo incident in two months
(Reuters) -Australian fertility group Monash IVF on Tuesday reported a new incident related to an embryo transfer, within a couple of months after reporting a similar case where a doctor accidentally implanted the wrong embryo. The latest incident, which occurred on June 5 at the company's Clayton laboratory, has been reported to regulatory bodies and the company's insurer, Monash said, issuing an apology to the impacted couple. The company is also conducting an internal investigation. The firm added that it is implementing additional verification processes and patient confirmation safeguards to prevent similar incidents in the future. The clinic owner in April reported a similar incident where an Australian woman gave birth to a stranger's baby due to a Monash fertility doctor's error. Shares of Monash are down about 31% since the news. The mix-up has drawn attention to an industry that was largely self-regulated until recently and raised concerns about security protocols at IVF clinics. The facilities are regulated by a mix of Australian industry bodies and state government agencies.
Yahoo
2 hours ago
- Yahoo
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937


Business Wire
2 hours ago
- Business Wire
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
BOSTON & SYDNEY--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. 'The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,' said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. 'Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry'. BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich.